BidaskClub downgraded shares of Halozyme Therapeutics (NASDAQ:HALO) from a buy rating to a hold rating in a research note released on Tuesday.

A number of other equities research analysts have also recently weighed in on the stock. Zacks Investment Research cut shares of Halozyme Therapeutics from a buy rating to a hold rating in a report on Monday, December 25th. Barclays cut shares of Halozyme Therapeutics from an overweight rating to a hold rating and upped their price objective for the stock from $16.00 to $19.00 in a report on Wednesday, November 22nd. Canaccord Genuity upped their price objective on shares of Halozyme Therapeutics from $17.00 to $19.00 and gave the stock a buy rating in a report on Wednesday, November 8th. BMO Capital Markets upped their price objective on shares of Halozyme Therapeutics from $15.00 to $18.00 and gave the stock a market perform rating in a report on Wednesday, November 8th. Finally, Piper Jaffray Companies upped their price objective on shares of Halozyme Therapeutics from $26.00 to $29.00 and gave the stock an overweight rating in a report on Monday, October 16th. One research analyst has rated the stock with a sell rating, five have issued a hold rating and three have given a buy rating to the company’s stock. The stock has an average rating of Hold and a consensus price target of $19.14.

Halozyme Therapeutics (NASDAQ HALO) traded up $0.30 during mid-day trading on Tuesday, reaching $20.36. 802,413 shares of the company were exchanged, compared to its average volume of 1,240,000. Halozyme Therapeutics has a 12 month low of $10.74 and a 12 month high of $21.13. The company has a market capitalization of $2,890.00, a P/E ratio of -29.94 and a beta of 2.09. The company has a current ratio of 3.46, a quick ratio of 3.37 and a debt-to-equity ratio of 2.01.

Halozyme Therapeutics (NASDAQ:HALO) last released its quarterly earnings results on Tuesday, November 7th. The biopharmaceutical company reported $0.02 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $0.06 by ($0.04). The company had revenue of $63.73 million during the quarter, compared to the consensus estimate of $58.95 million. Halozyme Therapeutics had a negative return on equity of 892.57% and a negative net margin of 53.17%. Halozyme Therapeutics’s quarterly revenue was up 100.1% on a year-over-year basis. During the same period in the previous year, the company earned ($0.23) earnings per share. equities research analysts anticipate that Halozyme Therapeutics will post 0.2 earnings per share for the current year.

Institutional investors and hedge funds have recently made changes to their positions in the business. Rhumbline Advisers grew its holdings in Halozyme Therapeutics by 6.6% in the third quarter. Rhumbline Advisers now owns 143,342 shares of the biopharmaceutical company’s stock worth $2,490,000 after purchasing an additional 8,903 shares during the period. Vanguard Group Inc. grew its holdings in shares of Halozyme Therapeutics by 9.5% during the second quarter. Vanguard Group Inc. now owns 9,595,212 shares of the biopharmaceutical company’s stock valued at $123,010,000 after buying an additional 831,654 shares during the last quarter. Alps Advisors Inc. grew its holdings in shares of Halozyme Therapeutics by 10.7% during the third quarter. Alps Advisors Inc. now owns 139,764 shares of the biopharmaceutical company’s stock valued at $2,428,000 after buying an additional 13,556 shares during the last quarter. Granite Investment Partners LLC grew its holdings in shares of Halozyme Therapeutics by 44.7% during the third quarter. Granite Investment Partners LLC now owns 818,505 shares of the biopharmaceutical company’s stock valued at $14,217,000 after buying an additional 252,998 shares during the last quarter. Finally, JPMorgan Chase & Co. grew its holdings in shares of Halozyme Therapeutics by 7.2% during the third quarter. JPMorgan Chase & Co. now owns 2,868,670 shares of the biopharmaceutical company’s stock valued at $49,915,000 after buying an additional 191,476 shares during the last quarter. Institutional investors and hedge funds own 84.45% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This piece of content was originally posted by Watch List News and is the property of of Watch List News. If you are viewing this piece of content on another website, it was stolen and republished in violation of international copyright and trademark laws. The correct version of this piece of content can be read at https://www.watchlistnews.com/bidaskclub-lowers-halozyme-therapeutics-halo-to-hold/1806107.html.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc is a biotechnology company focused on developing and commercializing oncology therapies. The Company operates in research, development and commercialization of human enzymes and other drug candidates. The Company’s segment also includes research and development activities and product sales of Hylenex recombinant.

Analyst Recommendations for Halozyme Therapeutics (NASDAQ:HALO)

Receive News & Ratings for Halozyme Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halozyme Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.